MRK · Merck & Co., Inc. · Documents
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →
Merck said the FDA wants trial data that include U.S. patients, after the Harmony CRL. Executives said the maturity of U.S. data matters more than the percentage of U.S. patients. They also described MK1084 as well tolerated.
Thomas H. Glocer notified the Board he intends to retire at the 2027 Annual Meeting of Shareholders, with no disagreement with the Company. Douglas M. Baker, Jr. will become independent lead director effective Jan. 1, 2027, succeeding Mr. Glocer.
Merck recorded a $9.0 billion R&D charge after acquiring Cidara Therapeutics, Inc. for $9.2 billion in May 2026. Worldwide sales increased 5% to $18.1 billion in the third quarter of 2026 amid pricing pressure.
Merck reported third-quarter 2026 sales of $18,085 million, up 5%, with GAAP EPS of $2.04 and non-GAAP EPS of $2.49, both including a one-time $0.12 per share charge tied to a SciBrunch license agreement. Full-year 2026 sales are now expected between $66.8 billion and $67.3 billion. Non-GAAP EPS guidance was narrowed and raised to between $2.77 and $2.82.
Merck & Co., Inc. elected Paul J. Diaz to its Board of Directors effective November 1, 2026, appointed him to the Audit Committee and Research Committee, and expanded the Board to 14 members. Diaz will stand for shareholder election in May 2027.